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Abstract
Background and Study Design: This study was undertaken as part of the UK LIMPRINT international study to
determine the number of people with chronic edema (CO) and its impact on health services. Overall 7436 with
CO were recruited in the main UK study from a range of health settings.
Methods and Results: Factors relating to subjective control of arm and leg CO were defined in the UK. A total of
1565 patients were included in the study with exclusions for: no limb swelling or not recorded (1669), having
concurrent arm/leg CO (272), control of assessment missing (5) and professional being unsure of control status of CO
(325). Arm swelling occurred in 953 (18.5%) with leg CO in 4212 (81.5%). Poor control was found in 1430 (27.2%)
and good control in 3735 (72.3%). Control of arm swelling was worse in men and control increased overall in those
aged over 45 years. In contrast control of CO worsened in those with leg CO with increasing age and multiple co-
morbidities. Obesity and cellulitis, particularly an episode in the last year were associated with poor control.
Independent risk factors for arm CO were : obesity, neurological disease and cellulitis in the last year and for leg CO,
obesity, poor mobility, heart disease, presence of a wound, cellulitis in the last year and duration of swelling.
Conclusion: Control of CO within specialized centers is complex due to sociodemographic and clinical comorbidities.
Keywords: control of swelling, chronic edema, arm, leg, risk factors, lymphedema, lymphoedema
Background to Lymphedema Services
in the United Kingdom
As in most countries of the world, provision of treat-ment for patients with Lymphedema in the United
Kingdom is poor. Historically services were only offered to
those suffering from Lymphedema following cancer treat-
ment, and those with primary and other forms of chronic
edema (CO) were denied access to care. This led to an in-
creasingly biased view that Lymphedema was only a mani-
festation of the cancer population rather than a complex
heterogenous population.
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The UK Lymphedema Framework
Nearly two decades ago funding was obtained from the
Kings Fund to develop a collaborative approach to try to
improve UK treatment provision. The project involved epi-
demiology, development of the Best Practice Document, and
evaluation of a model of care. This work has been published
in full.1–4 In 2006, the partners within this project were also
successful in obtaining NHS Drug Tariff approval for Lym-
phedema products to be listed for prescribing in the commu-
nity through general practices and community nurses. This
opened the way for community-based treatment and stimu-
lated investment from the medical device industry to develop
new products and invest in this area. Despite this there is still
patchy care provision across the United Kingdom with only
Wales having a national strategy for care provision.5
Since then much effort has been provided by the National
Lymphoedema Partnership to improve the national recom-
mendations for treatment. The UK Lymphoedema Framework
led to the development of the International Lymphoedema
Framework, which embraces the importance of partnership
working and addressing some of the key questions interna-
tionally that must be addressed.
Development of the Definition of CO
in the United Kingdom
The recognition of the complex patients presenting to a
national UK specialist services two decades ago led to the
development of the term ‘‘chronic oedema.’’1 This was used in
the prevalence study carried out in 2003 and is defined below:
‘‘Chronic oedema is a broad term used to describe
oedema which has been present for more than three
months and involves one or more of the following ar-
eas: limbs, hands/feet, upper body (breast/chest wall,
shoulder, back), lower body (buttocks, abdomen),
genital (scrotum, penis, vulva), head, neck or face.’’
Thus, ‘‘chronic oedema’’ can be considered to be an um-
brella term, which includes not only conventional ‘‘Lym-
phoedema’’ but also chronic swelling which may have a more
complex cause.
Prevalence Studies in the UK
The first study to use the definition of CO was reported in
2003.1 The aim of the study was to determine the magnitude
of the problem of CO in health services within an urban area
of London, United Kingdom, and to assess the likely impact of
edema on use of health resources, employment, and patient’s
quality of life. The study used a questionnaire-based survey
given to health professionals followed by an interview and
clinical assessment in a random sample. Health professionals
from dedicated Lymphedema services, specific outpatient
clinics, hospital wards, and community services (GP clinics
and district nurses) were contacted to provide information on
patients from within the geographical area who were known to
suffer with CO of greater than 3 months duration.
Within the catchment area with a population of 619,000
people, 823 patients had CO (crude prevalence 1.33/1000).
Prevalence increased with age (5.4/1000 in those aged >65
years) and was higher in women (2.15 vs. 0.47/1000). Only
529 (64%) were receiving treatment, despite two specialist
Lymphedema clinics within the catchment area. Of 228 pa-
tients interviewed, 78% had edema lasting >1 year. Over the
previous year, 64/218 (29%) had had an acute infection in the
affected area, with 17/64 (27%) being admitted to hospital for
intravenous antibiotics. Mean length of stay for this condition
was 12 days, with an estimated mean cost of £2300 (2003
data). Edema caused time off work in >80% and affected
employment status in 9%. Quality of life was below normal,
with 50% experiencing pain or discomfort from their edema.
Using an extrapolation of these figures, it was estimated
that at least 100,000 patients were suffering in the United
Kingdom alone. However, it is acknowledged that this will be
an underestimate of the true prevalence within the general
population.
This methodology was repeated over 10 years later in an
urban population of the East Midlands in the United King-
dom.2 This cross-sectional study was carried out in Derby
City (United Kingdom), which has a population of*247,100.
Data were obtained from 10 sources, namely: the inpatients of
one acute and one community hospital, one specialist and
three nonspecialist outpatient clinics (dermatology, plastic
surgery, and diabetic foot clinic), all community nursing
services, general practices (n = 41), and nursing/residential
homes (n = 26) in the catchment area.
Within the study population of Derby City residents, 971
patients were identified with CO (estimated crude prevalence
3.93 per 1000, 95% CI 3.69–4.19). The prevalence was
highest among those aged 85 or above (28.75 per 1000) and
was higher among women (5.37 per 1000) than men (2.48 per
1000). The prevalence among hospital inpatients was 28.5%.
Only 5 (3%) patients in the community population had edema
related to cancer or cancer treatment. Patients with cancer
related lymphedema were usually treated by hospital-based
services in Derby. Of the 304 patients identified with edema
from the Derby hospitals or community health services, 121
(40%) had a concurrent leg ulcer.
The Role of Professional Judgment
of Control of Swelling
Internationally agreed definitions of outcome of CO
management are lacking. While limb volume measurement is
frequently cited as the primary outcome of many studies,
there are many variations to this technique, and a lack of
standardization makes interpretation between studies diffi-
cult. Therefore, clear conceptualization of how professionals
and patients define control of swelling is urgently needed.
Within the original epidemiology conducted in the United
Kingdom, professionals who identified participants were asked
to make a subjective assessment of whether they considered that
the participants CO was well controlled.1 They also identified
whether they were receiving treatment and the site of swelling.
All personnel involved in the study were trained in the data
collection methods and had access to Lymphedema experts if
they were unsure whether the CO was stable. Within the sample
of 823 participants health professionals considered control of
swelling to be better in women compared to men (62.5% vs.
44.3%). In the youngest age group (<45 years), only 11% were
reported to have uncontrolled swelling. This increased with age
to 59.0% in those aged >85 years. Professionals reported that
patients with arm edema experienced better control than
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patients with leg edema (85% vs. 42%). Nearly 80% (77.9%) of
patients who were being actively treated for their CO had
control, compared with just 29.4% in those not being offered
treatment. Despite the subjective nature of this question it would
appear that there are important associations influencing control
of swelling that are not only related to the complex patient
population but also to effective care provision.
Overall Summary of LIMPRINT
in the United Kingdom
The LIMPRINT study was undertaken in different health
settings in the United Kingdom. The study adopted the
methods and data collection tools previously defined in the
LIMPRINT methodology.6 Results from these studies have
been published separately.7,8 In summary, 7436 partici-
pants were recruited from the following settings: specialist
Lymphedema services (n = 5660), community nursing ser-
vices (n = 1440), inpatient hospital facilities (NUH trust)
(n = 298), and other settings, including a prison (n = 38)
(Table 1). The population was predominantly female
(71.8%) with a mean age of 66.6 years. Obesity was com-
mon, affecting 37.1% with a further 20.7% defined as
morbidly obese. While half could walk unaided, 12% were
either chair or bedbound. Swelling affecting the leg was the
most common (79.7%) with arm edema affecting 21.2%
and a further 12% having midline swelling with concurrent
limb swelling. The majority had secondary CO (87.4%) that
was unrelated to having cancer (67.5%). A further 12.5%
were defined as suffering from primary Lymphedema.
Methods to Assess Subjective Control of Swelling
Within Specialist Lymphedema Services
Setting and sampling frame
The study to investigate professional views on control of
swelling was carried out in three regional Lymphedema
Services in the Midlands and north of England, United
Kingdom (Derby, LOROS, Leicester, and St. Oswald’s
Hospice, Newcastle). These services participated in the main
UK LIMPRINT study. Data were obtained using the same
methodology in each area. Approval for the studies was
granted by the local Research and Governance Committees
for each service area and complied with their regulations.
Identification of patients through the creation
of master lists
A master list was created using the data systems and
clinical notes within each service and checked for duplication
and deaths. The reasons for all exclusions were recorded. All
forms were checked against the master list to ensure complete
data capture. Individualized and anonymized participant
numbers were allocated to avoid duplication of recruitment.
The questionnaire and process of clarification were piloted
with the team at St Oswald’s Hospice.
The following information was used to collect individual
data on subjective control of swelling:
 The current CO status was obtained from the clinical
notes based on their last clinical visit and limb volume
measurement
Table 1. Total UK LIMPRINT Study: (N = 7436) Demographic, Mobility, and Swelling Related Problems
Home care N (%) Inpatient N (%) Specialist service N (%) Other N (%) Total N (%)
N 1440 298 5660 38 7436
Gender
Female 842 (58.47) 163 (54.70) 4309 (76.13) 26 (68.42) 5340 (71.81)
Male 598 (41.53) 135 (45.30) 1351 (23.87) 12 (31.58) 2096 (28.19)
Age
Mean (SD) 76.3 (13.8) 73.0 (16.4) 64.4 (15.8) 69.1 (12.0) 66.6 (16.7)
Obesity
Under weight 132 (9.17) 27 (9.06) 64 (1.13) 5 (13.16) 228 (3.07)
Normal weight 805 (55.90) 136 (45.64) 1945 (34.37) 24 (63.16) 2910 (39.14)
Obese 408 (28.33) 102 (34.23) 2244 (39.65) 7 (18.42) 2761 (37.14)
Morbidly obese 95 (6.60) 33 (11.07) 1406 (24.85) 2 (5.26) 1536 (20.66)
Lower limb mobility
Walks unaided 409 (28.42) 74 (24.83) 3343 (59.08) 2 (5.26) 3828 (51.50)
Walks with aid 760 (52.81) 157 (52.68) 1794 (31.71) 25 (65.79) 2736 (36.81)
Chair bound 181 (12.58) 34 (11.41) 498 (8.80) 11 (28.95) 724 (9.74)
Bedbound 89 (6.18) 33 (11.07) 23 (0.41) 0 (0) 145 (1.95)
Swelling
Arm/hand * 56 (19.05) 1210 (21.43) 5 (13.16) 1271 (21.26)
Leg/foot * 279 (94.90) 4451 (78.85) 38 (100) 4768 (79.77)
Midline * 31 (10.54) 685 (12.13) 3 (7.89) 719 (12.03)
Classification
Primary * 11 (3.69) 734 (13.12) 0 745 (12.57)
Secondary * 287 (96.31) 4859 (86.88) 38 (100) 5184 (87.43)
Secondary
Cancer * 31 (10.80) 1646 (34.07) 8 (21.05) 1685 (32.68)
Noncancer * 256 (89.20) 3185 (65.93) 30 (78.95) 3471 (67.32)
*Not recorded.
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 Newly presenting patients who were not yet receiving
treatment were noted
 Patients receiving complex decongestive therapy
(CDT) at the time of recruitment were noted
 Patients in maintenance therapy (self-management)
with skin care, exercise, self-massage, and compression
hosiery were noted
 A history of cellulitis and an episode of cellulitis in the
last year were noted
 Classification of control of swelling was clarified with
the therapists treating the patient and where necessary
with the lead physician within each service
Statistical Methods
Data analysis
Data were entered onto a bespoke data entry and validation
system.6 After completion of patient entry, the data were
downloaded to an Excel spreadsheet and exported into Stata
12 (StataCorp, TX), where statistical analyses were under-
taken. After exclusions, patients were allocated to two
groups, either those with arm swelling or those with leg
swelling. Factors associated with control in these subsets
were then undertaken. The primary method of analysis was
logistic regression with either control or poor/no control as
the dependent variable. Odds ratios (OR) and 95% confi-
dence intervals were used to describe the difference between
the independent risk categories and the dependent variable.
The p-values were derived from the Chi squared results de-
rived from the logistic regression. Finally, an analysis was
undertaken to identify independent factors that were associ-
ated with the presence of CO in the cohort.
Results
In total there were 7436 patients seen by health professional
in the study areas of the United Kingdom, Table 1. The ma-
jority of these were seen in specialist lymphedema services
FIG. 1. Study flow of participants.
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(5660, 76.1%). As expected most (71.8%) were female, with a
mean (SD) age of 66.6 (16.7) years. While those seen in Home
Care were mainly of normal weight, a greater proportion in
Specialist services were either considered to be obese or
morbidly obese. As expected, those patients seen at home or as
inpatients had greater mobility deficits compared with spe-
cialist services. The distribution of sites of swelling was sim-
ilar between inpatients and specialist services with the
majority experiencing edema of the leg or foot. More patients
were diagnosed with primary lymphedema in the specialist
services compared with inpatients, who also experienced a
greater proportion with cancer-related secondary disease.
In total 5767 patients with CO of one or more limbs were
entered into the study of factors associated with control of
swelling. Patients with both arm and leg swelling were ex-
cluded from this analysis (n = 272). Of the remainder 5495
were assessed for control of swelling. Of these, 325 were
excluded on the basis that the professional was either unsure
or did not know whether the swelling was controlled or not.
The total number of patients analyzed was 5165, of which
1430 (27.7%) were assessed by their health professional as
having poor control with 3735 (72.3%) having good control
(Fig. 1). Of the total 3938 (76.3%) were women with a mean
(SD) age of 65.3 (15.9) years. The 1225 men had a mean (SD)
age of 64.9 (15.8) years. For the analysis, patients were di-
vided into 953 (18.5%) with arm edema and 4212 (81.5%)
with leg edema and were analyzed separately.
Control of Arm Swelling
Table 2 gives demographic and mobility information on
the 953 patients with arm edema. There was some evidence
that men were less likely to have control over their CO than
for women in this group. Those over 45 years had better
control than those under, although there was some evidence
that the very elderly group (>85 years) may have experienced
lower control (OR = 0.77), although the confidence intervals
were wide for this group (0.31, 1.88).
Control of CO was strongly associated with the levels of
obesity, with higher BMI associated with poorer control.
Underweight patients also appeared to have lower control,
although this was based on few patients (n= 15) compared
with those with normal weight. Limited range of arm
movement had little impact on control compared with pa-
tients with full range of movement.
Table 3 examines the relationship between comorbidities
and control of CO. Strong associations with control of CO
were found with the presence of neurological disease and an
acute infection (cellulitis) in the previous year. Other asso-
ciations were present but did not achieve statistical signifi-
cance. These may be, in part, due to small numbers of patients
with these conditions.
Details of the swelling are given in Table 4. While there was
a large difference between the levels of control and swelling
duration, it appears that this difference is stable over the pa-
tients whose CO was present for more than one year. In the
subgroup with secondary cause (n= 930) CO control was more
likely in the patients with cancer as a cause of their swelling but
not for those with metastatic disease. The small number of
patients with other secondary causes of CO meant that little
could be gleaned from these analyses.
Table 5 shows the associations between treatments and
control. There was good evidence that skin care advice and
use of compression garments were associated with better
control, with little evidence of an association with antibiotic
usage or massage. Multilayer bandaging was associated with
poorer control of the swelling.
Control of Leg Swelling
Table 6 gives information on the control of leg swelling in
relation to demographic details. While the difference be-
tween genders was less than for arm edema (OR = 0.84 vs.
0.57), the larger sample size achieved a standard level of
statistical difference ( p = 0.017). The observations on age
were contradictory to those with arm edema. Patients over the
Table 2. Control of Arm Swelling: Demographic and Mobility Problems (n = 953)
No control Control
N % N % OR 95%CI p-value
Gender
Female 164 90.61 729 94.43 1.00
Male 17 9.39 43 5.57 0.57 (0.32–1.02) 0.060
Age
<45 years 12 6.67 39 5.05 1.00
45–64 years 92 51.11 322 41.71 1.08 (0.54–2.14) 0.010
65–74 years 34 18.89 215 27.85 1.95 (0.93–4.08)
75–84 years 28 15.56 161 20.85 1.77 (0.83–3.79)
85+ years 14 7.78 35 4.53 0.77 (0.31–1.88)
Obesity
Normal weight 83 45.86 423 54.86 1.00
Underweight 6 3.31 9 1.17 0.29 (0.10–0.85) 0.021
Obese 75 41.44 298 38.65 0.78 (0.55–1.10)
Morbidly obese 17 9.39 41 5.32 0.47 (0.26–0.87)
Arm mobility
Full range of movement 128 70.72 561 72.67 1.00
Limited range of movement 53 29.28 209 27.07 0.90 (0.63–1.29) 0.56
No function 0 0 2 0.26 —
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Table 3. Control of Arm Swelling: Comorbidities (n = 953)
No control Control
N % N % OR 95%CI p-value
Diabetes
Absent 158 87.29 698 90.41 1.00
Present 23 12.71 74 9.59 0.73 (0.44–1.20) 0.21
Heart failure/CHD
Absent 168 92.82 735 95.21 1.00
Present 13 7.18 37 4.79 0.65 (0.34–1.25) 0.20
Neurological disease
Absent 1702 93.92 753 97.54 1.00
Present 11 6.08 19 2.46 0.39 (0.18–0.83) 0.015
Peripheral arterial disease
Absent 179 98.90 770 99.74
Present 2 1.10 2 0.26 0.17*
Wound present
Absent 174 96.13 757 98.06 1.00
Present 7 3.87 15 1.94 0.53 (0.22–1.31) 0.16
History of cellulitis
Absent 120 66.30 563 72.93 1.00
Present 61 33.70 209 27.07 0.73 (0.52–1.03) 0.076
Cellulitis in past year
Absent 148 81.77 718 93.01 1.00
Present 33 18.23 54 6.99 0.34 (0.21–0.54) <0.001
*Fisher’s exact test.
Table 4. Control of Arm Swelling: Details and Classification of Swelling (n= 953)
No Control Control
N % N % OR 95%CI p-value
Swelling duration (n = 951)
<1 year 42 23.20 51 6.62 1.00
1–2 years 23 12.71 125 16.23 4.48 (2.45–8.19) <0.001
2–5 years 42 23.20 206 26.75 4.04 (2.39–6.84)
5–10 years 44 24.31 215 27.92 4.02 (2.39–6.78)
>10 years 30 16.57 173 22.47 4.75 (2.70–8.34)
Classification (n= 950)
Primary 5 2.76 9 1.17 1.00
Secondary 176 97.24 760 98.83 2.40 (0.79–7.25) 0.12
Secondary (n = 930)
Cancer 157 89.71 710 94.04 1.00
Noncancer 18 10.29 45 5.96 0.55 (0.31–0.98) 0.043
Cancer (n= 867)
Cancer treatment
Absent 16 10.19 20 2.82 1.00
Present 141 89.81 690 97.18 3.91 (1.98–7.74) <0.001
Cancer metastatic
Absent 140 89.17 684 96.34 1.00
Present 17 10.83 26 3.66 0.31 (0.17–0.59) <0.001
Noncancer (n = 63)
Venous
Absent 17 94.44 39 86.67
Present 1 5.56 6 13.33 0.66*
Immobility
Absent 16 88.89 41 91.11
Present 2 11.11 4 8.89 0.99*
Obesity
Absent 17 94.44 45 100.0
Present 1 5.56 0 0 0.29*
Other
Absent 3 16.67 6 13.33
Present 15 83.33 40 86.67 0.71*
*Fisher’s exact test.
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age of 45 were less likely to have control of their swelling,
although again there appeared to be little difference between
the older age groups. Patients who were either underweight or
overweight had better control of their swelling than those of
normal weight, although this only achieved a statistical dif-
ference in the underweight and morbidly obese patients.
Mobility was an important factor in control of swelling with
strong association between poor mobility and failure to
control the swelling. All comorbidities listed in Table 7 were
strongly related to a lack of edema control.
There was a strong positive relationship between swelling
duration and control (Table 8), which was similar to arm
edema. Secondary edema was associated with poorer control,
and noncancer edema was related to poorer control although
with a lack of statistical significance. Swelling associated
with cancer treatment as the cause of swelling was strongly
associated with good control, whereas metastatic cancer was
associated with poor control. Venous disease as a cause of
swelling was associated with good control, while immobility
and obesity causes were both strongly related to poor control.
Table 9 gives the use of treatments in relation to control of
swelling. Skin care advice, massage, and the use of com-
pression garments were associated with good control of the
edema. The use of multilayer bandaging and antibiotic usage
were both related to poor control.
Multivariable Analysis
Table 10 gives the multivariable analysis of the intrinsic
factors in the control of swelling in patients with arm
swelling. Factors identified for poor control were high levels
of obesity, presence of neurological disease, recent infection,
Table 5. Control of Arm Swelling: Previous and Current Treatments (n= 953)
No control Control
N % N % OR 95%CI p-value
Massage
Absent 124 68.51 521 67.49 1.00
Present 57 31.49 251 32.51 1.05 (0.741–1.48) 0.79
Skin care advice
Absent 28 15.47 33 4.27 1.00
Present 153 84.53 739 95.73 4.10 (2.41–6.98) <0.001
Compression garment
Absent 21 11.60 54 6.99 1.00
Present 160 88.40 719 93.01 1.75 (1.02–2.97) 0.040
Multilayer bandaging
Absent 146 80.66 727 94.17 1.00
Present 35 19.34 45 5.83 0.26 (0.16–0.42) <0.001
Antibiotics
Absent 169 93.37 741 95.98 1.00
Present 12 6.63 31 4.02 0.59 (0.30–1.17) 0.13
Table 6. Control of Leg Swelling: Demographic and Mobility Problems (N = 4212)
No control Control
N % N % OR 95%CI p-value
Gender
Female 872 69.82 2175 73.41 1.00
Male 377 30.18 788 26.59 0.84 (0.72–0.97) 0.017
Age
<45 years 113 9.05 373 12.59 1.00
45–64 years 376 30.13 961 32.43 0.77 (0.61–0.99)
65–74 years 283 22.68 720 24.30 0.77 (0.60–0.99) <0.001
75–84 years 312 25.00 639 21.57 0.62 (0.48–0.80)
85+ years 164 13.14 270 9.11 0.50 (0.37–0.66)
Obesity
Normal weight 329 26.34 898 30.31 1.00
Underweight 24 1.92 35 1.18 0.53 (0.31–0.91)
Obese 488 39.07 1186 40.03 0.89 (0.76–1.05) 0.004
Morbidly obese 408 32.67 844 28.48 0.76 (0.64–0.90)
Leg mobility
Walks unaided 445 35.63 1648 55.62 1.00
Walks with aid 589 47.16 1038 35.03 0.48 (0.41–0.55) <0.001
Chair bound 187 14.97 264 8.91 0.38 (0.31–0.47)
Bedbound 28 2.24 13 0.44 0.13 (0.06–0.24)
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Table 7. Control of Leg Swelling: Comorbidities (n= 4212)
No control Control
N % N % OR 95%CI p-value
Diabetes
Absent 963 77.10 2432 82.08 1.00
Present 286 22.90 531 17.92 0.74 (0.63–0.86) <0.001
Heart failure/CHD
Absent 992 79.42 2586 87.28 1.00
Present 257 20.58 377 12.72 0.56 (0.47–0.67) <0.001
Neurological disease
Absent 1107 88.63 2708 91.39 1.00
Present 142 11.37 255 8.61 0.73 (0.59–0.91) 0.005
Peripheral arterial disease
Absent 1223 97.92 2935 99.06 1.00
Present 26 2.08 28 0.94 0.45 (0.26–0.77) 0.004
Wound
Absent 950 76.06 2772 93.55 1.00
Present 299 23.94 191 6.45 0.22 (0.18–0.27) <0.001
History of cellulitis
Absent 660 52.88 1700 57.39 1.00
Present 588 47.12 1262 42.61 0.83 (0.73–0.95) 0.007
Cellulitis in past year
Absent 959 76.78 2652 89.50 1.00
Present 290 23.22 311 10.50 0.39 (0.33–0.46) <0.001
Table 8. Control of Leg Swelling: Classification of Swelling (n= 4212)
No control Control
N % N % OR 95%CI p-value
Swelling duration
<1 year 154 12.34 78 2.63 1.00
1–2 years 129 10.34 223 7.53 3.41 (2.41–4.83)
2–5 years 260 20.83 624 21.07 4.74 (3.48–6.45) <0.001
5–10 years 281 22.52 859 29.00 6.04 (4.45–8.18)
>10 years 424 33.97 1178 39.77 5.49 (4.09–7.36)
Classification
Primary 118 9.54 541 18.53 1.00
Secondary 1119 90.46 2379 81.47 0.46 (0.38–0.57) <0.001
Secondary cause n = 3492
Cancer 142 12.69 342 14.41 1.00 0.17
Noncancer 977 87.31 2031 85.59 0.86 (0.70–1.06)
Cancer (n= 484)
Cancer treatment
Absent 45 31.69 28 8.19 1.00
Present 97 68.31 314 91.81 5.20 (3.08–8.78) <0.001
Cancer metastatic
Absent 95 66.90 314 91.81 1.00
Present 47 33.10 28 8.19 0.18 (0.11–0.30) <0.001
Noncancer (n = 2925)
Venous
Absent 591 60.49 1149 56.57 1.00
Present 386 39.51 882 43.43 1.18 (1.01–1.37) 0.042
Immobility
Absent 482 49.33 1248 61.45 1.00
Present 495 50.67 783 38.55 0.61 (0.52–0.71) <0.001
Obesity
Absent 601 61.51 1379 67.90 1.00
Present 376 38.49 652 32.10 0.76 (0.64–0.89) <0.001
Lymphatic filariasis
Absent 973 99.59 2029 99.90 0.09*
Present 4 0.41 2 0.10
Other
Absent 440 45.04 799 39.34 1.00 0.001
Present 537 54.96 1232 60.66 1.26 (1.08–1.47)
*Fisher’s exact test.
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and short duration of CO. For patients with leg disease the
independent factors were high levels of obesity, poor mo-
bility, presence of heart disease, presence of a wound, recent
infection, and short duration of CO (Table 11).
Discussion
Findings from this study would indicate that understanding
the subjective control of swelling based on professional as-
sessment is complex. Many different sociodemographic, clin-
ical, and treatment issues influence control. The distribution of
the site of swelling is important and indicates that leg edema is
associated with a worsening prognosis with increasing age that
is aggravated significantly by the level of obesity and immo-
bility. Cellulitis has emerged as an important factor in many of
the LIMPRINT studies. In this analysis an episode of cellulitis
in the last year was found to be related to poor control.9
The results from the earlier study that assessed subjective
control of swelling were supported in this analysis and would
indicate that even within specialist services that are providing
CDT control of CO may still be difficult to achieve and maintain
due to the complexities of the patient population.10 It is therefore
likely that control of swelling will be worse within general health
services with poor access to specialist services. Previous re-
search has shown that control of swelling over time is not
maintained after CDT and that there is a poorer response to those
who require repeated episodes of CDT.11
Table 9. Control of Leg Swelling: Previous and Current Treatments (n = 4212)
No control Control
N % N % OR 95%CI p-value
Massage
Absent 1120 89.67 2494 84.17 1.00
Present 129 10.33 469 15.83 1.63 (1.33–2.01) <0.001
Skin care
Absent 346 27.70 171 5.77 1.00
Present 903 72.30 2792 94.23 6.26 (5.13–7.63) <0.001
Compression garment
Absent 572 45.80 361 12.18 1.00
Present 677 54.20 2602 87.82 6.09 (5.21–7.12) <0.001
Multilayer bandaging
Absent 969 77.58 2659 89.74 1.00
Present 280 22.42 304 10.26 0.40 (0.33–0.47) <0.001
Antibiotics
Absent 1141 91.35 2840 95.85 1.00
Present 108 8.65 123 4.15 0.46 (0.35–0.60) <0.001
Table 10. Independent Factors Associated
with Control of Arm Swelling
Odds ratio 95% CI z-score p-value
Obesity
Normal 1.00
Underweight 0.28 0.09–0.86 -2.42 0.015
Obese 0.73 0.51–1.06
Morbidly obese 0.45 0.24–086
Neurological disease
Absent 1.00
Present 0.32 0.14–0.70 -2.83 0.005
Infection within past year
Absent 1.00
Present 0.31 0.19–0.50 -4.71 <0.001
Swelling duration
<1 year 1.00 1.00
1–2 years 4.96 2.66–9.26
2–5 years 4.20 2.44–7.24 4.49 <0.001
5–10 years 4.60 2.66–7.92
>10 years 5.11 2.85–9.14
Table 11. Independent Factors Associated
with Control of Leg Swelling
Odds ratio 95% CI z-score p-value
Obesity
Normal 1.00
Underweight 1.07 0.56–2.03 -3.39 0.001
Obese 0.78 0.65–0.94
Morbidly obese 0.69 0.57–0.84
Mobility
Walks unaided 1.00
Walks with aid 0.56 0.48–0.66 -8.85 <0.001




Present 0.74 0.61–0.89 -3.09 0.002
Wound present
Absent 1.00
Present 0.28 0.23–0.35 -11.86 <0.001
Infection within past year
Absent 1.00
Present 0.47 0.38–0.56 -7.81 <0.001
Swelling duration
<1 year 1.00 1.00
1–2 years 3.06 2.12–4.42
2–5 years 4.83 3.48–6.71 9.64 <0.001
5–10 years 6.33 4.57–8.77
>10 years 5.52 4.03–7.57
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Caution over the link to treatment and control of swelling
in this study should be made. While compression hosiery was
associated with better control than multilayer bandaging this
may simply be a reflection that new patients are requiring
CDT and have a more severe presentation of CO rather than
those who are self-managing with compression hosiery dur-
ing the maintenance phase of treatment.
Limitations
Several limitations must be acknowledged within the
study. As previously discussed, objective descriptions and
methods to define control of swelling do not currently ex-
ist.12,13 Every attempt was made to standardize and reduce
the number of people collecting data within this study and to
seek clarification over professional judgment of control;
however, these will always be subject to bias in the absence
of clear definitions and correlation against other objective
measures.
Despite this, the sample size is large, and every attempt
was made to reduce the natural biases that may exist. Data
were excluded from all participants where the decision about
control of swelling was uncertain and access to specialized
Lymphedema teams assisted in increasing the accuracy of the
decisions that were made.
A cross-sectional study is also limited to an assessment at
one time point, and longitudinal studies are required to ex-
amine the natural history of this phenomena. Further studies
in more general populations would also help to define this
important area more clearly and to correlate these with robust
clinical and other psychosocial outcomes.
Conclusion
Professional judgment of control of CO in arm and leg CO is
complex. To avoid double counting, patients with both arm and
leg CO were excluded (N=272). A total of 5165 patients were
included in the study with exclusions for: no limb swelling or
not recorded (1669), having concurrent arm/leg CO (272),
control of assessment missing (5) and professional being un-
sure of control status of CO (325).
Arm swelling occurred in 953 (18.5%) with leg CO in 4212
(81.5%). Poor control was found in 1430 (27.2%) and good
control in 3735 (72.3%). Control of arm swelling was worse in
men and control increased overall in those aged over 45 years.
In contrast control of CO worsened in those with leg CO with
increasing age and multiple co-morbidities. Obesity and cel-
lulitis, particularly an episode in the last year were associated
with poor control. Independent risk factors for arm CO were,
obesity, neurological disease and cellulitis in the last year and
for leg CO, obesity, poor mobility, heart disease, presence of a
wound, cellulitis in the last year and duration of swelling.
This study highlights the complexity of patients with CO
and the challenges associated with obtaining control of CO
within specialist services. The research highlights the im-
portance of addressing the complex issues associated with
lower limb swelling and the importance of issues such as
obesity and immobility which are more challenging to in-
fluence. Risk factor analysis within this study will help the
prioritization of treatment for high risk patient groups who
may require more intensive therapy to standardize their
condition. Research to improve on measurement of outcomes
is urgently needed.
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